Innovations in Care
We provide programs and services that transform the lives of people affected by neuromuscular disease.
Introducing ISEMBYLD. The first and only FDA-approved treatment for SMA to directly target muscle.
October 6th, 2026
1:30 PM ET
Live, Virtual Webinar
Attendees will learn about the role of muscle in SMA, the importance of directly targeting muscle, how ISEMBYLD works with current SMN2-targeted treatments, its clinical trial results and safety profile, and resources available to support patients throughout their treatment journey.
Thank you to our supporter:
